
## Alexander Y Deneka

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8353315/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Musashi-2 (MSI2) supports TGF-β signaling and inhibits claudins to promote non-small cell lung cancer (NSCLC) metastasis. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 6955-6960.	7.1	120
2	Mechanisms for nonmitotic activation of Aurora-A at cilia. Biochemical Society Transactions, 2017, 45, 37-49.	3.4	41
3	Targeting the Epidermal Growth Factor Receptor in EGFR-Mutated Lung Cancer: Current and Emerging Therapies. Cancers, 2021, 13, 3164.	3.7	35
4	Ganetespib limits ciliation and cystogenesis in autosomalâ€dominant polycystic kidney disease (ADPKD). FASEB Journal, 2018, 32, 2735-2746.	0.5	32
5	A Novel HSP90 Inhibitor–Drug Conjugate to SN38 Is Highly Effective in Small Cell Lung Cancer. Clinical Cancer Research, 2016, 22, 5120-5129.	7.0	28
6	Association of <i>TP53</i> and <i>CDKN2A</i> Mutation Profile with Tumor Mutation Burden in Head and Neck Cancer. Clinical Cancer Research, 2022, 28, 1925-1937.	7.0	28
7	Embryonal Fyn-associated substrate (EFS) and CASS4: The lesser-known CAS protein family members. Gene, 2015, 570, 25-35.	2.2	22
8	Tumor-Targeted Drug Conjugates as an Emerging Novel Therapeutic Approach in Small Cell Lung Cancer (SCLC). Cancers, 2019, 11, 1297.	3.7	21
9	Synthetic Lethal Targeting of Mitotic Checkpoints in HPV-Negative Head and Neck Cancer. Cancers, 2020, 12, 306.	3.7	19
10	Unexpected Activities in Regulating Ciliation Contribute to Off-target Effects of Targeted Drugs. Clinical Cancer Research, 2019, 25, 4179-4193.	7.0	18
11	Musashi-2 (MSI2) regulates epidermal growth factor receptor (EGFR) expression and response to EGFR inhibitors in EGFR-mutated non-small cell lung cancer (NSCLC). Oncogenesis, 2021, 10, 29.	4.9	18
12	Opposing Effects of Inhibitors of Aurora-A and EGFR in Autosomal-Dominant Polycystic Kidney Disease. Frontiers in Oncology, 2015, 5, 228.	2.8	14
13	Identification of evolutionarily conserved DNA damage response genes that alter sensitivity to cisplatin. Oncotarget, 2017, 8, 19156-19171.	1.8	11
14	Tumor-targeted SN38 inhibits growth of early stage non-small cell lung cancer (NSCLC) in a KRas/p53 transgenic mouse model. PLoS ONE, 2017, 12, e0176747.	2.5	9
15	Musashi 2 (MSI2) expression as an independent prognostic biomarker in non-small cell lung cancer (NSCLC). Journal of Thoracic Disease, 2021, 13, 1370-1379.	1.4	7
16	<i>Nedd9</i> Restrains Autophagy to Limit Growth of Early Stage Non–Small Cell Lung Cancer. Cancer Research, 2021, 81, 3717-3726.	0.9	7
17	Evaluation of the Small-molecule BRD4 Degrader CFT-2718 in Small-cell Lung Cancer and Pancreatic Cancer Models. Molecular Cancer Therapeutics, 2021, 20, 1367-1377.	4.1	6
18	NEDD9 sustains hexokinase expression to promote glycolysis. Oncogenesis, 2022, 11, 15.	4.9	6

Alexander Y Deneka

#	Article	IF	CITATIONS
19	Prognostic role and biologic features of Musashi-2 expression in colon polyps and during colorectal cancer progression. PLoS ONE, 2021, 16, e0252132.	2.5	5
20	Musashi 2 (MSI2) expression as an independent prognostic biomarker in non-small cell lung cancer (NSCLC) Journal of Clinical Oncology, 2020, 38, e21583-e21583.	1.6	3
21	An improved method of delivering a sclerosing agent for the treatment of malignant pleural effusion. BMC Cancer, 2019, 19, 614.	2.6	2
22	NEDD9 Restrains dsDNA Damage Response during Non-Small Cell Lung Cancer (NSCLC) Progression. Cancers, 2022, 14, 2517.	3.7	1
23	Abstract 1584: Musashi-2 (MSI2) drives TGFBR1/SMAD3 dependent partial EMT and supports VEGFR2 expression and metastasis of human and mouse NSCLC cells. , 2016, , .		0
24	Prognostic significance of Musashi 2 (MSI2) RNA-binding protein expression in precancerous polyps and during colorectal cancer (CRC) progression Journal of Clinical Oncology, 2020, 38, e16009-e16009.	1.6	0